International Stem Cell Corp. (ISCO) Leverages Superior Stem Cell Technology to Capitalize on Massive Opportunities
International Stem Cell Corp. is a California biotechnology company that has developed a stem cell technology based on parthenogenesis, the creation of pluripotent human stem cells from unfertilized oocytes (eggs). Parthenogenetic stem cells have a number of advantages over stem cells derived through other means.
First, parthenogenetically derived stem cells do not involve the destruction of human embryos, thus avoiding the ethical issues associated with embryonically sourced stem cells. Second, because the oocytes are unfertilized, parthenogenetic stem cells have a duplicate set of human leukocyte antigen (HLA) genes. This greatly reduces the possibility of the derived cells being rejected by an individual’s immune system, meaning that a single cell line can be suitable for the treatment of millions of individuals, and even a small number of cell lines could provide “immune matched” cells to a significant percentage of the world’s population. Third, parthenogenetic stem cells are pluripotent, able to differentiate into all sorts of specialized body cells. In summary, parthenogenetic stem cells represent a combination of advantages not shared by stem cells from other sources.
ISCO is focused on three therapeutic markets, with revenue potential of over $4.2 billion. The company is already working on applying parthenogenetic stem cells to diseases of the eye, liver, and brain, in addition to making them available to others for research. The company has developed a broad intellectual property portfolio, with freedom to operate and strong patent protection. For example, there are more than 1 million sufferers in the $2.2B market for Parkinson’s disease, currently being researched by ISCO, and there is no pluripotent stem cell based competition.
The company also has commercial operations, in the form of Lifeline Cell Technology, a business to business research products company that manufactures and markets high-quality human primary cells, media, and reagents; and Lifeline Skin Care, a company that develops, manufactures, and markets anti-aging skin care products based on growth factors and peptides extracted from human
parthenogenetic stem cells.
For additional information on ISCO, visit the company’s website at www.InternationalStemCell.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net